Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044229 | 0.86 | BACE1 (0.37) | BACE1 | |
| SCHEMBL6044403 | 0.86 | LMNA (0.37) | MAPTBACE1LMNAHTTKMT2A | |
| SCHEMBL6044320 | 0.86 | SMN1; SMN2 (0.35) | MAPTBACE1LMNAHTTKMT2A | |
| SCHEMBL6044247 | 0.85 | MAPT (0.41) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL6043698 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL6044267 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL6044471 | 0.79 | BACE1 (0.39) | BACE1 | |
| SCHEMBL6044958 | 0.79 | BACE1 (0.37) | BACE1 | |
| SCHEMBL6043542 | 0.77 | BACE1 (0.36) | BACE1 | |
| SCHEMBL6044130 | 0.76 | NTRK1 (0.36) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1430032-A2 | SUBSTITUTED AMIDES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Elan Pharmaceuticals, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027068-A2 | SUBSTITUTED AMINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | ELAN PHARMACEUTICALS, INC. (US) | 2003-04-03 | — | — | WO | claimed |
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100196-A1 | Substituted amines for the treatment of alzheimer's disease | BACE1, APP, BACE2 | MAPT 27/4885BACE1 1/4885LMNA 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.